ORMP is leveraging its strong balance sheet to invest in early stage companies, primarily focusing on the medical & biopharma space. ORMP has substantial liquidity as it both advances its oral drug delivery platform and pursues strategic opportunities, including strategic investments. The company received ~$27m on its Scilex investment in 3Q25, with the principal on the Scilex investment now fully repaid. Moreover, since ORMP's strategic investment in DRTS, DRTS shares have appreciated significantly. Separately, last week ORMP announced that it has adopted a Rights Agreement designed to help the company fight a prospective hostile takeover attempt.
